Learhill Pharma Unlimited Company
Summary
Learhill Pharma Unlimited Company was set up on Wednesday the 23rd of March 2016. Their current partial address is Galway, and the company status is Liquidation. The company's current directors have been the director of 55 other Irish companies between them; 14 of which are now closed. Learhill Pharma Unlimited Company has 4 shareholders. This Irish company shares its Eircode with at least 38 other companies.
Credit Score
- Latest Credit Movement:
- Date of Last Movement:18/04/2025
- Latest Accounts Filed:20/02/2024
- Report Based On Accounts:30/04/2023
- Next Set of Accounts Due:31/01/2025
Credit Report
- Credit Report & Financials
- Company Printout Report
- Directors & Owners Report
- Bad Debt Judgments Report
- Mortgages Report
€9
Company Vitals
- Company Name:Learhill Pharma Unlimited Company
- Time in Business:9 Years
- Company Number:579411
- Company Size:Small Company
- Current Status:LIQUIDATION
- Principal Activity:[4618] Agents Specialised in the Sale of Other Particular Products
- May Trade As:
- Largest Company Shareholder:
- Registered Address:Michael McEvoy & Co.,
Seville House,
5 New Dock Street,
The Docks, Galway, Ireland
H91 CKV0 - RiskWatch: Form E2: Notice of Appointment of Liquidator(s)
Effective Date 13/03/2025
€3
Directors
Purchase either the Standard Company Report or a Credit Report to view details on the directors of this company.
Documents
| Document | Pages | Effective | Received | Buy |
|---|---|---|---|---|
| Form G1 - Special Resolution to Wind up - Form G1 - Special Resolution to Wind up | 2 | 13/03/2025 | 27/03/2025 | |
| NEW! E1-SAP Declaration of Solvency Summary App Procd | 6 | 13/03/2025 | 27/03/2025 | |
| Form E2: Notice of Appointment of Liquidator(s) | 2 | 13/03/2025 | 27/03/2025 | |
| OTHER DIRECTORSHIP LIST | 1 | 24/01/2025 | 04/02/2025 | |
| Form B1B73 - Annual Return and Change of ARD | 5 | 24/01/2025 | 04/02/2025 | |
| AMENDED CONSTITUTION | 10 | 18/10/2017 | 27/11/2018 | |
| Certificate of Incorporation | 1 | 23/03/2016 | 12/02/2016 |